Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0L2VT
|
|||
| Former ID |
DNCL002408
|
|||
| Drug Name |
PV-10
|
|||
| Synonyms |
632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Cutaneous melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 3 | [1], [2] | |
| Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 3 | [3] | ||
| Hepatocellular carcinoma [ICD-11: 2C12.02; ICD-10: C22.0; ICD-9: 155] | Phase 1 | [4] | ||
| Metastatic liver cancer [ICD-11: 2C12; ICD-10: C22] | Phase 1 | [1] | ||
| Neuroendocrine cancer [ICD-11: 2B72.1; ICD-9: 209] | Phase 1 | [1] | ||
| Company |
Provectus Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H2Cl4I4Na2O5
|
|||
| Canonical SMILES |
C1=C2C(=C(C(=C1I)[O-])I)OC3=C(C(=C(C=C3C24C5=C(C(=C(C(=C5Cl)Cl)Cl)Cl)C(=O)O4)I)[O-])I.[Na+].[Na+]
|
|||
| InChI |
1S/C20H4Cl4I4O5.2Na/c21-9-7-8(10(22)12(24)11(9)23)20(33-19(7)31)3-1-5(25)15(29)13(27)17(3)32-18-4(20)2-6(26)16(30)14(18)28;;/h1-2,29-30H;;/q;2*+1/p-2
|
|||
| InChIKey |
KCQREHTWEUECQT-UHFFFAOYSA-L
|
|||
| CAS Number |
CAS 632-69-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | ClinicalTrials.gov (NCT02288897) PV-10 Intralesional Injection vs Systemic Chemotherapy for Treatment of Locally Advanced Cutaneous Melanoma. U.S. National Institutes of Health. | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.